Return to homepagePandemic Pact

To develop a safe, immunogenic & stable vaccine for all populations against the novel coronavirus COVID-19 which is affordable and accessible for all countries

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    N/A

  • Funder

    BIRAC

  • Principal Investigator

    Vikram Paradkar

  • Research Location

    India

  • Lead Research Institution

    Biological E Ltd.

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Phase 1 clinical trial

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Clinical Trial, Phase I

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

The antigen derived from the Receptor Binding Domain RBD of the Spike Protein S on the surface of SARS-CoV-2 used as a vaccine candidate. Bio E has employed classical, proven vaccine technology by formulating purified protein RBD with known adjuvants Alum and CpG . The RBD of S1 subunit binds to the Angiotensin Converting Enzyme-2 i.e. ACE2 receptor on host cell membrane and facilitates virus entry. RBD protein expression is in yeast Pichia pastoris. Phase I/II study enrolments are completed for all 4 cohorts 3 DSMBs for Phase I safety study are completed serology IgG & nAb assays ongoing.